clofibric acid has been researched along with Benign Neoplasms in 6 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| "Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied." | 1.28 | Flavone acetic acid and plasma protein binding. ( Brodfuehrer, J; Chan, K; Corbett, T; Heilbrun, L; Valeriote, F, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Balendiran, GK | 2 |
| Pahan, K | 1 |
| Verma, M | 1 |
| Martin, HJ | 1 |
| Haq, W | 1 |
| O'Connor, TR | 1 |
| Maser, E | 1 |
| Brodfuehrer, J | 1 |
| Valeriote, F | 1 |
| Chan, K | 1 |
| Heilbrun, L | 1 |
| Corbett, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III[NCT04507867] | 80 participants (Actual) | Interventional | 2020-09-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total number of patients with gastrointestinal symptoms at the end of follow-up at day 40.Those symptoms perceived abdominal region (pain, burn, pressure, nausea, vomiting) (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 4 |
| Intervention Group | 3 |
The ratio between the water assimilated into the body and that lost from the body, in milliliters. (NCT04507867)
Timeframe: It is evaluated on day 3 of hospital stay (duration approximately 10 minutes).
| Intervention | milliliters (Mean) |
|---|---|
| Control Group | 123.4 |
| Intervention Group | 456.6 |
Patients who were intubated during their hospital stay and died before completing follow-up on day 40. (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 5 |
| Intervention Group | 1 |
The need to continue with supplemental oxygen at hospital discharge. Categories: 1. Yes, 2. No. (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 23 |
| Intervention Group | 26 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Leukocytes <10x10^3/μL | 3 |
| Leukocytes >10x10^3/μL | 5 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Neutrophils <80% | 0 |
| Neutrophils >80% | 8 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| RCP <150 mg/L | 1 |
| RCP >150 mg/L | 7 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Urea <40 mg/dL | 4 |
| Urea >40 mg/dL | 4 |
Association between the presentation of certain laboratory parameters taken at baseline with the overall mortality of discharged patients compared to deceased patients. (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Fibrinogen <700 mg/dL | 2 |
| Fibrinogen >700 mg/dL | 6 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Procalcitonin <0.5 ng/mL | 4 |
| Procalcitonin >0.5 ng/mL | 4 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Ureic Nitrogen <22 mg/dL | 4 |
| Ureic Nitrogen >22 mg/dL | 4 |
Refers to the subjective sensation of increased abdominal pressure without an increase in abdominal size, the number of defecations were quantified at day 3 and compared between both groups. (NCT04507867)
Timeframe: Day 3
| Intervention | defecations (Mean) |
|---|---|
| Control Group | 0.81 |
| Intervention Group | 1.41 |
Is a visible increase in abdominal girth.1. Present, 2. Absent. (NCT04507867)
Timeframe: Day 3
| Intervention | percent of participants (Number) |
|---|---|
| Control Group | 51.6 |
| Intervention Group | 19.4 |
Total number of patients who died before day 40 of follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 1 |
Overall survival, the total number of patients included in the study and completed a 40-day follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 33 |
| Intervention Group | 39 |
the total number of patients with oxygen saturation >90% on day 3 of their hospital stay. (NCT04507867)
Timeframe: day 3.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 34 |
| Intervention Group | 37 |
"The Bristol Stool Form Scale categorizes stools into one of seven stool types ranging from type 1 (hard lumps) to type 7 (watery diarrhea). Type 3 and 4 were considered Normal." (NCT04507867)
Timeframe: day 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 13 |
Persistence of clinical signs and symptoms that arise after developing COVID-19, and are not explained by an alternative diagnosis. 1. Present. 2. Absent. (NCT04507867)
Timeframe: Day 40.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 9 |
| Intervention Group | 8 |
total number of patients included in the study who progressed to mechanical ventilation during the first 10 days of hospital stay. (NCT04507867)
Timeframe: 10 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 3 |
The oxygen saturation without supplementary oxygen is taken at the control appointment 40 days after hospital discharge. (NCT04507867)
Timeframe: day 40
| Intervention | percentage (Mean) |
|---|---|
| Control Group | 90.39 |
| Intervention Group | 92.08 |
Total number of patients who were intubated, extubated, discharged and completes the 40 day follow-up (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 2 |
| Intervention Group | 2 |
It is recorded for how many days the treating doctor asked the patients to continue to administer supplemental oxygen after hospital discharge (NCT04507867)
Timeframe: day 40
| Intervention | days (Mean) |
|---|---|
| Control Group | 57.6 |
| Intervention Group | 43.8 |
Is defined as at least a 5% reduction in weight from the baseline level.Total number of patients with weight loss at the end of follow-up at day 40 (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 8 |
Difference in oxygen delivery between the baseline period and day 3 of hospital stay in each group. (NCT04507867)
Timeframe: baseline and day 3
| Intervention | Liters (L) (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 5.9 | 6 |
| Intervention Group | 6 | 4.5 |
Is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders, includes 9 items, which evaluate the presence of depressive symptoms based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders version 4, during the last 2 weeks, how often the patient presented depressive symptoms. According to the sum of the score obtained, the following 4 categories will be considered: 0-4 minimum existence or absence of depressive symptoms; 5-9 = mild depressive symptoms; 10-14 = moderate depressive symptoms; 15-19 = moderate to severe depressive symptoms; 20-27 = severe depressive symptoms. (NCT04507867)
Timeframe: baseline and hospital discharge
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Hospital discharge | |
| Control Group | 3.66 | 1.50 |
| Intervention Group | 5.3 | 1.9 |
Quick-Sequential Organ Failure Assessment (qSOFA) score gives 0 to 3 points. ≥2 in the setting of suspected infection had a high predicted in-hospital mortality rate and could be considered septic. (NCT04507867)
Timeframe: Baseline and Day 3
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 0.42 | 0.51 |
| Intervention Group | 0.65 | 0.43 |
4 reviews available for clofibric acid and Benign Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Fibrates in the chemical action of daunorubicin.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Antibiotics, Antineoplastic; Clofibric Acid; Daunorubicin; | 2009 |
Lipid-lowering drugs.
Topics: Alzheimer Disease; Clofibric Acid; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2006 |
2 other studies available for clofibric acid and Benign Neoplasms
| Article | Year |
|---|---|
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzot | 2008 |
Flavone acetic acid and plasma protein binding.
Topics: Animals; Binding Sites; Binding, Competitive; Blood Proteins; Clofibric Acid; Flavonoids; Humans; In | 1990 |